Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 11, 1996, Pages 1319-1326

  Reverter, Joan Carles ^a   Tàssies, Dolors ^a   Font, Josep ^a   Monteagudo, Joan ^a   Escolar, Ginés ^a   Ingelmo, Miguel ^a   Ordinas, Antoni ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

antiphospholipid syndrome; free protein S; monocytes; thrombosis; tissue factor

Indexed keywords

PHOSPHOLIPID ANTIBODY; PROCOAGULANT; PROTEIN S; THROMBOPLASTIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0029911062     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.11.1319     Document Type: Article

References (53)

1. Harris EN. Antiphospholipid antibodies. Br J Haematol. 1990;74:1-9.
2. Bowie WEJ, Thomson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Clin Invest. 1963;62:416-430.
3. Harris EN. The antiphospholipid syndrome: an introduction. In: Harris EN, Exner T, Hughes GRV, Asherson RA, eds. Phospholipid Binding Antibodies. Boca Raton, Fla: CRC Press; 1991: 373-386.
4. Carreras LO, De Freyn G, Machin SJ, Vermylen JG, Deman R, Spitz B, Van Asshe A. Arterial thrombosis, intrauterine death and 'lupus' anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet. 1981;1:244-246.
5. Schorer AE, Wickham NW, Watson KV. Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol. 1989;71:399-407.
6. Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost. 1989;61:175-177.
7. Ruíz-Argüelles G, Ruíz-Argüelles A, Lobato-Mendizabal E, Díaz-Gómez F, Pacheco-Pantoja E, Drenkar C, Alarcön Segovia D. Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus. Am J Hematol. 1991;37:9-13.
8. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol. 1991; 77:354-359.
9. Freyssinet JM, Weisel ML, Gauchy J, Boneu B, Cazenave JP. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin: a mechanism for thrombosis. Thromb Haemost. 1986;55:309-313.
10. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood. 1989;74:2426-2432.
11. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol. 1990;76:101-107.
12. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. Total and free protein S in systemic lupus erythematosus. Thromb Res. 1990;60:237-240.
13. Parke AL, Weinstein RE, Bona RD, Maier DB, Walker FJ. The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. Am J Med. 1992;93:49-56.
14. Ruíz-Argüelles G, Ruíz-Argüelles A, Alarcón Segovia D, Drenkar C, Villa A, Cabiedes J, Presno-Bernal M, Delezé M, Ortïz-López R, Vázquez-Prado J. Natural anticoagulants in systemic lupus erythematosus: deficiency of protein S bound to C4bp associates with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. J Rheumatol. 1991;18:552-558.
15. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C. or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81: 2618-2625.
16. Escolar G, Font J, Reverter JC, López-Soto A, Garrido M, Cervera R, Ingelmo M, Castillo R, Ordinas A. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation: studies in a perfusion system. Arterioscler Thromb. 1992;12:196-200.
17. Reverter JC, Tàssies D, Escolar G, Font J, López-Soto A, Ingelmo M, Ordinas A. Effect of plasma from patients with primary antiphospholipid syndrome in platelet function in a collagen rich perfusion system. Thromb Haemost. 1995;13:132-137.
18. Hasselaar P, Derksen RHWM, Oosting JD, Blokzijl L, De Groot PG. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemost. 1989;62:654-660.
19. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol. 1993;168:206-210.
20. Schved JF, Gris JC, Ollivier V, Wautier JL, Tobelem G, Caen J. Procoagulant activity of endotoxin or tumor necrosis factor activated monocytes is enhanced by IgG from patients with lupus anticoagulant. Am J Hematol. 1992;41:92-96.
21. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol. 1994;153:1328-1332.
22. Rustin MHA, Bull HA, Machin SJ, Isenberg DA, Snaith ML, Dowd PM. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol. 1988;90:744-748.
23. Oosting JD, Derksen RHWM, Blokzijl L, Sixma JJ, De Groot PG. Antiphospholipid positive sera enhance endothelial cell procoagulant activity: studies in a thrombosis system. Thromb Haemost. 1992; 68:278-284.
24. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol. 1992;29:170-176.
25. Rapaport S, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb. 1992;12:1111-1121.
26. Luther Th, Flössel C, Hietschhold V, Koslowsky R, Müller M. Flow cytometric analysis of tissue factor (TF) expression on stimulated monocytes: comparison to procoagulant activity of mononuclear blood cells. Blut. 1990;61:375-378.
27. Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Semin Hematol. 1992;29:202-212.
28. Herbert JM, Savi P, Laplaca MC, Lale A. IL-4 inhibits LPS, IL-1β and TFα induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett. 1992;310:31-33.
29. Schwartz BS, Edgington TS. Immune complex-induced human monocyte procoagulant activity, I: a rapid unidirectional lymphocyte-instructed pathway. J Exp Med. 1981;154:892-906.
30. Tan EM, Cohen AS, Fries JF, Masi AT, Mc Shane DJ, Rothfield NE, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
31. Exner T, Triplett DA, Tabemer D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants: SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost. 1991;65:320-322.
32. Cervera R, Font J, López-Soto A, Casals F, Pallarés L, Bové A, Ingelmo M, Urbano-Márquez A. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis. 1990;49: 109-113.
33. Harris EN, Gharavi AE, Tincani A, Chan JKH, Englert H, Mantelli P, Allegro F, Ballestrieri G, Hughes GRV. Affinity purified anticardiolipin and anti-DNA antibodies. J Clin Lab Immunol. 1985; 17:155-162.
34. Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with new chromogenic substrates (S-2238 and chromozyme TH). Thromb Res. 1977;11:549-553.
35. Bertina RM, Broekmans AW, Van Es-Krommenhoek C, Van Wijngaarden A. The use of a functional and immunological assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemost. 1984;51:1-5.
36. Amiral J, Grosley M, Boyer-Neumanm C, Marfing-Koka A, Peynaud-Debayle E, Wolf M, Meyer D. New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form. Blood Coagul Fibrinolysis. 1994;5:179-186.
37. Friberger P. Chromogenic peptide substrates: their use for the assay factors in the fibrinolytic and plasma kallicrein-kinin systems. Scand J Clin Lab Invest. 1982;42(suppl 162):49-54.
38. Pelzer H, Schwartz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 1991;65:153-159.
39. Pelzer H, Schwartz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost. 1988;59:101-106.
40. Hasselaar P, Perkson R, Blokzijl L, De Groot PG. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemost. 1988;59:80-85.
41. Dudley DJ, Mitchell MD, Branch DW. Pathophysiology of antiphospholipid antibodies: absence of prostaglandin-mediated effects on cultured endothelium. Am J Obstet Gynecol. 1990;162: 953-959.
42. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, Hughes GRV. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis. 1988;47:849-854.
43. Arfors L, Vesterqvist O, Johnsson H, Gréen K. Increased thromboxane formation in patients with antiphospholipid syndrome. Eur J Clin Invest. 1990;20:607-612.
44. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinol. 1994;5:37-41.
45. Mackman N, Morrisey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gene, a highly regulated cellular ceptor that initiates the coagulation protease cascade. Biochemistry. 1989;28:1755-1762.
46. Karmochkine M, Bérard M, Piette JC, Cacoub P, Godeau P, Boffa MC. The effect of sera with antiphospholipid antibodies on endothelial cell procoagulant activity is dependent upon the charge of the phospholipids against which they are directed. Thromb Res. 1994; 74:435-440.
47. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990;87:4120-4124.
48. 2-GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol. 1992;82: 565-570.
49. . Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GRV. Beta-2-glycoprotein I reactivity of monoclonal antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 1994;37:1453-1461.
50. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71:1-8.
51. Nemerson Y, Gentry R. An ordered addition, essential activation model of the tissue factor pathway of coagulation: evidence for a conformational cage. Biochemistry. 1986;25:4020-4033.
52. Barstad RM, Hamers MJAG, Kierulf P, Westvik AB, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Thromb Vasc Biol. 1995;15:11-16.
53. Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol. 1994;88:364-371.